NEW YORK, Sept. 25, 2008 (GLOBE NEWSWIRE) -- Veteran business journalist Sasha Salama joins Steven A. Kriegsman, Director, President and CEO, CytRx Corporation (CYTR) to discuss the company's industry, strategy, financials and positioning.
Click here to view video: http://investor.shareholder.com/ceosignature/webcast.cfm?mediaid=33194&k=31119B5F6511BE962F066837FB15A70B
Steven A. Kriegsman has been a Director, President and Chief Executive Officer of CytRx Corporation (Nasdaq:CYTR) since July 2002. He also serves as a Director of RXi Pharmaceuticals Inc. (Nasdaq:RXII) and Chairman of its Compensation Committee. Mr. Kriegsman also serves as a Director of Hythiam, Inc (Nasdaq:HYTM) and Chairman of its Audit Committee. He previously served as a Director and Chairman of Global Genomics from June 2000 until its merger with CytRx Corporation in July 2002. Mr. Kriegsman is the Chairman of the Board and Founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. Mr. Kriegsman has a B.S. degree with honors from New York University in accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Mr. Kriegsman was formerly a Certified Public Accountant with KPMG in New York City. From June 2003 until February 2008, he served as a Director, and he is the former Chairman of the Audit Committee of Bradley Pharmaceuticals, Inc. In February 2006, Mr. Kriegsman received the Corporate Philanthropist of the Year Award from the Greater Los Angeles Chapter of the ALS Association and in October 2006, he received the Lou Gehrig Memorial Corporate Award from the Muscular Dystrophy Association. Mr. Kriegsman has been active in various charitable organizations including the Biotechnology Industry Organization, the ALS Association, the Los Angeles Venture Association, the Southern California Biomedical Council, and the Palisades-Malibu YMCA.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. CytRx drug development pipeline includes six programs in clinical development, including tamibarotene in registration studies for the treatment of acute promyelocytic leukemia (APL). In addition to a portfolio of oncology programs, CytRx is developing two drug candidates identified using the company's proprietary, industry leading molecular chaperone technology which aims to repair or degrade mis-folded proteins associated with disease. The Company owns and operates a research and development facility in San Diego, California. CytRx also maintains a 45% equity interest in RXi Pharmaceuticals (Nasdaq:RXII). For more information on the Company, visit www.cytrx.com.
For more information about NASDAQ CEO Signature Series interviews, call 978/461-3141.
The NASDAQ CEO Signature Series logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4839